Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $401,000 with net income of −$19M.
Q1 2026 key financials · XBRL
- Revenue
- $401,000
- Net income
- −$19M
- −10.6% YoY
- Operating margin
- -4775.6%
- EPS (diluted)
- −$0.27
- −8.0% YoY
Source: XBRL data from the PULSE BIOSCIENCES, INC. (PLSE) Q1 2026 10-Q on SEC EDGAR. USD.
PULSE BIOSCIENCES, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- 2026 Realignment prioritizing electrophysiology development and reducing cardiac surgery and Vybrance investments
- Cardiac catheter: 96% one-year procedural success, approximately 65-minute procedures, 177 patients evaluated
- Cash deployment: $12.9M net proceeds from May 11, 2026 ATM stock sale
- Near-term outlook: FDA IDE cardiac catheter study targeting 215 patients across up to 30 sites
Risk Factors
- No explicit new or changed risk identified; provided section contains carried-forward risk disclosures
- Additional capital dependence, with potential dilution, restrictive debt covenants, or scaled-back operations
- FDA and other regulatory uncertainty over clinical approvals, reimbursement, tariffs, and changing requirements
- Slow Vybrance adoption among surgeons due to limited reimbursement, clinical evidence, and experience
- Revenue concentration in the nPulse System and NPS platform, with no significant revenue-producing operations
- Approximately 72% voting control held by Co-Chairman Robert Duggan, limiting minority stockholder influence
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PULSE BIOSCIENCES, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.